Home About Us Our Technology News + Media Investor Relations Contact Us
Company Press Releases Publications


Company Press Releases                                                                               Back

MedaSorb Technologies Adds Strategic Technology Patent

Friday October 27, 8:30 am ET

MONMOUTH JUNCTION, N.J., Oct. 27, 2006 (PRIMEZONE) -- MedaSorb Technologies (OTC BB:MSBT.OB - News) announced today that it has acquired ownership of Patent No. 6,884,829 from Robert Albright, Ph.D., a scientific consultant to the Company, in the completion of a prearranged agreement. The patent covers important chemistry for the production and efficacy of the company's adsorbent technology which is the cornerstone of the both the BetaSorb(tm) and CytoSorb(tm) products. The technology includes the identification of a number of dispersants that can be utilized in the manufacturing process to simultaneously form the external hemocompatible coating and the adsorbent polymer in a single step. This process further strengthens MedaSorb's intellectual property portfolio and could significantly reduce both the time and cost of manufacturing the CytoSorb(tm) polymer.

Al Kraus, the CEO of MedaSorb, said, ``We are pleased to complete the assignment of this important patent to our intellectual property portfolio. As the company moves towards FDA approval for our CytoSorb(tm) product, we look to benefit from the cost and time savings this technology offers us in the manufacturing process.''

About MedaSorb Technologies, Inc.

MedaSorb Technologies Corporation is a medical device company headquartered in Monmouth Junction, New Jersey. MedaSorb is a development stage company that has developed and is preparing to commercialize a blood purification technology that efficiently removes toxic compounds from circulating blood.

MedaSorb's initial products (CytoSorb(tm) and BetaSorb(tm)), are known medically as hemoperfusion devices and incorporate proprietary adsorbent polymer technology. MedaSorb believes that potential healthcare applications for its products include: adjunctive treatment and/or prevention of sepsis; prevention of damage to organs donated for transplant prior to organ harvest; prevention of post-operative complications of cardiac surgery; short and long-term treatment of kidney failure; and Drug Detoxification.

MedaSorb's management team is led by Al Kraus, President and CEO, who has more than twenty-five years' experience managing companies in the dialysis, medical device products, personal computer and custom software industries. Other members of MedaSorb's management team include James Winchester, MD, CMO, Vincent Capponi, COO, and David Lamadrid, CFO.

Forward-Looking Statements

This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release are not promises or guarantees and are subject to risks and uncertainties that could cause our actual results to differ materially from those anticipated. These statements are based on management's current expectations and assumptions and are naturally subject to uncertainty and changes in circumstances. We caution you not to place undue reliance upon any such forward-looking statements. Actual results may differ materially from those expressed or implied by the statements herein. MedaSorb Technologies Corporation believes that its primary risk factors include, but are not limited to: ability to successfully develop commercial operations; dependence on key personnel; acceptance of the Company's medical devices in the marketplace; the outcome of pending and potential litigation; obtaining government approvals, including required FDA approvals; compliance with governmental regulations; reliance on research and testing facilities of various universities and institutions; the ability to obtain adequate financing in the future when needed; product liability risks; limited manufacturing experience; limited marketing, sales and distribution experience; market acceptance of the Company's products; competition; unexpected changes in technologies and technological advances; and other factors detailed in the Company's Current Report on Form 8-K filed with the SEC on July 6, 2006, which is available at http://www.sec.gov


MedaSorb Technologies Corporation
David Lamadrid
(732) 329-8885 ext. 816


Source: MedaSorb Technologies

Home | Career Opportunities | Contact Us
© 2008 CytoSorbents Incorporated All Rights Reserved